There’s new Vaccine coming. Novavax.
It uses mRNA tech, and creates Spike Proteins, but puts the mRNA into a culture of Moth Cells, then purifies and separates the resultant spike proteins to make the vaccine.
My question is simple:
Will this fix enough of the “problems” of the mRNA direct injection to be “worth it”, and will that make it safe enough to be something I’d take?
First off, not having the spike protein created by my own cells will mean a more deterministic quantity will be injected. Individual variation in lifetime of mRNA and number of transcriptions will be eliminated.
Second, there is no chance for prolonged replication inside your body. You get the jab, and that’s it.
The Spike Protein will be more effectively localized to the injection site. (One small scrap of nano-particle mRNA drifting off to, say, a liver cell, can create a lot of S spike particles there and will also present them in the context of a liver cell membrane). Further, they spike protein will not be presented on the surface of your cells adjacent to your cellular proteins, but will be a free floating thing. IMHO this means far less chances for an Auto-Immune response to the combined “spike+you” presentation.
Fourth, it does not contain PEG PolyEthylene Glycol. A substance that many people react to with an allergic response as it is in many cosmetic and personal care items, so lots of exposure.
Overall, I’m thinking it will be a major improvement in safety. But will it be enough?
Downside? It still focuses on the Spike Protein so still consists of the part that changes the most and causes the damage.
Novavax COVID-19 Vaccine Demonstrates 89.3% Efficacy in UK Phase 3 Trial
First to Demonstrate Clinical Efficacy Against COVID-19 and Both UK and South Africa Variants
• Strong efficacy in Phase 3 UK trial with over 50% of cases attributable to the now-predominant UK variant and the remainder attributable to COVID-19 virus
• Clinical efficacy demonstrated in Phase 2b South Africa trial with over 90% of sequenced cases attributable to prevalent South Africa escape variant
It goes through a lot more about the trials and includes pretty pictures of the Spike Protein atomic model. This bit about South Africa had me wondering (I’ve bolded the troubling bit):
Prior COVID-19 Infection with Original Strain May Not Provide
Protection Against South Africa 501Y.V2 Escape Variant
• Nearly 1/3 of study participants had prior COVID-19 infection
• COVID-19 case rate in placebo group not impacted by baseline
• NVX-CoV2373 first vaccine with clinical data on protection
against 501Y.V2 escape variant
Sooo… If I’m reading that right, the South African escape variant is happy to infect folks who already had Chinese Wuhan Covid once before. No?
So the vaccines have selected for a mutant with greater powers that now is novel enough to infect those already immune to the original. That’s how I read it. I hope that’s not correct.
There’s 27 total pages, if you want more, hit the link.
Novavax has created a fourth COVID-19 vaccine using moth cells and tree bark. Instead of an mRNA vaccine (Pfizer, Moderna) or a viral vector vaccine (Johnson & Johnson), Novavax is a subunit protein vaccine.
Infectious diseases expert Diana Florescu, MD, led the phase 3 clinical trial of the Novavax vaccine at the University of Nebraska Medical Center (UNMC). “Diversity in vaccine production helps increase the number of patients vaccinated,” says Dr. Florescu. “Some might not accept mRNA vaccines, while others may be allergic to certain ingredients.”
For example, some are allergic to polyethylene glycol (PEG), an ingredient in the mRNA (Pfizer and Moderna) vaccines. There’s no polyethylene glycol (PEG) in Novavax.
How does the Novavax vaccine work?
The Novavax COVID-19 vaccine contains a protein (made using moth cells) plus an adjuvant (made from tree bark). An adjuvant is an ingredient added to boost a person’s immune response, creating higher levels of antibodies.
The Novavax vaccine uses a telltale piece of the coronavirus: the notorious spike protein. All alone, the spike protein is harmless and can’t cause COVID-19. When your immune system encounters the lonely spike protein, it produces antibodies against it. This gives you protection against future COVID-19 infection.
“Unlike mRNA vaccines, the spike protein is already premade in the Novavax vaccine. It’s a shortcut,” explains Dr. Florescu. “All the synthesis happens outside the body and we just give the end product: the spike protein.”
Like other COVID-19 vaccines, Novavax does not cause COVID-19 infection. It can’t get you sick. This vaccine doesn’t contain either live or inactivated virus.
How did they get the spike protein?
The Novavax method uses moth cells to make spike proteins:
Researchers select the desired genes that create certain SARS-CoV-2 antigens (spike protein).
Researchers put the genes into a baculovirus, an insect virus.
The baculovirus infects moth cells and replicates inside them.
These moth cells create lots of spike proteins.
Researchers extract and purify the spike proteins.
“The Novavax vaccine has no genetic material, only proteins,” says Dr. Florescu. “The vaccine technology is more traditional, and it’s very similar to a protein-based influenza vaccine.”
Influenza vaccines have also used this moth cell factory method.
What does the adjuvant (soapbark tree extract) do?
Adjuvants increase the immune response to a vaccine. In this vaccine, soapbark tree extract adjuvant makes achieving immunity possible with a smaller dose of the spike protein.
Matrix-M is the adjuvant used by Novavax. It is based on a saponin extracted from the soapbark tree (Quillaja saponaria). The soapbark extract encourages immune cells to activate, generating a more potent immune response.
Saponins are found naturally in various plant species like beans and green peas. They’re used in agriculture, animal feeds, veterinary vaccines and human food. Saponins can boost immune responses to proteins. Using the Matrix-M adjuvant, a smaller dose of spike protein achieves the desired immune response.
See how well the Novavax vaccine performed in phase 3 clinical trials here.
I’m somewhat more willing to accept Soap Bark Tree extract as an adjuvant (since folks could get it in a cut naturally anyway) and at least it isn’t graphene (a Chinese Paper shows it works as an adjuvant) or Aluminium.
It is still missing any capsule proteins so will still have issues with S protein mutations and vaccine escape, but short of actually getting the disease I’m not seeing a lot of options right now.
So what do you’all think: Is this “better enough” to be worth the jab? Or not?
I’m thinking it addresses most of my personal concerns.
I have high allergic response to “crap”, and especially a lot of “bathroom crap” sets me off, so that might be PEG.
I have a bit of auto-immune issues already (mild arthritis) so don’t want to poke that Auto-Immune bear with Spike proteins presenting on my own cell surfaces.
I tend to a bit of idiosyncratic metabolism and I’d not want to discover that my particular quirks included slow mRNA degradation and prolonged spike protein production.
Looks to me like this one addresses all of those, while also covering more “variants”.
My only residual concern is that the Spike Protein IS the damaging agent. OTOH, it ought to be kept more localized to the injection site (no ‘wandering mRNA’) and is of a fixed and minimal quantity.
For more, see here:
We are committed to delivering novel products that leverage our innovative proprietary recombinant nanoparticle vaccine technology to prevent a broad range of infectious diseases. We produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats.
Recombinant Nanoparticle Vaccine Technology
Our recombinant nanoparticle vaccine technology combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic particles that target a variety of viral pathogens. Our recombinant vaccine engineering takes a new approach to provide robust and functional immunity, which may be more efficacious than naturally occurring immunity or traditional vaccines. Using innovative proprietary recombinant nanoparticle vaccine technology, we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats.
RECOMBINANT NANOPARTICLE ADVANTAGES
Promote superior immunogenicity and better functional immunity via our Sf9/BV insect cell platform to efficiently express large antigens and particles.
Ability to manufacture and produce proteins that are properly folded and modified, which can be critical for functional, protective immunity.
Matrix-M™ adjuvant technology stimulates strong responses
Novavax’ saponin-based Matrix-M improves immune responses and enables vaccine dose-sparing.
Matrix-M adjuvant is a valuable component of vaccine development, providing multiple immune system enhancements, a well-understood mechanism of action, and robust clinical experience where it was shown to be well tolerated in human studies to date.
Further down that panel, in a part that does not let me do ‘copy paste’ so is likely an image, it says:
Increases neutralizing antibodies and induces long lasting memory B cells which enhance B-cell and recruit and increase the the frequency of CD4+ and CD8+ T Cells that enhance T-cell immunity.
That’s missing in the Pfizer / Moderna set.
But is it true?
Only time and deaths can tell.
But at least they are saying all the right things.
Bang it around. See what makes sense and what’s daft. Does it survive close scrutiny by a pack of Scruiteneers? Or is this just another case of the “Triumph of Hope over Experience?”